Differential methylation of a CpG site in the CD95-ligand promoter predicts the response to therapy with APG101 in glioblastoma. (July 2016) - Gieffers, C.; Merz, C.; Sykora, J.; Kunz, C.; Thiemann, M.; Wiestler, B.; Wick, W.; Fricke, H.